CN111956660A - 用含碘消毒液雾化防治病毒性呼吸道疾病的方法 - Google Patents
用含碘消毒液雾化防治病毒性呼吸道疾病的方法 Download PDFInfo
- Publication number
- CN111956660A CN111956660A CN202010781011.3A CN202010781011A CN111956660A CN 111956660 A CN111956660 A CN 111956660A CN 202010781011 A CN202010781011 A CN 202010781011A CN 111956660 A CN111956660 A CN 111956660A
- Authority
- CN
- China
- Prior art keywords
- iodine
- iodophor
- preventing
- liquid
- viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 title claims abstract description 56
- 239000011630 iodine Substances 0.000 title claims abstract description 56
- 229910052740 iodine Inorganic materials 0.000 title claims abstract description 56
- 230000003612 virological effect Effects 0.000 title claims abstract description 10
- 238000000034 method Methods 0.000 title claims abstract description 9
- 239000000645 desinfectant Substances 0.000 title claims abstract description 8
- 208000023504 respiratory system disease Diseases 0.000 title claims abstract description 7
- 241000700605 Viruses Species 0.000 claims abstract description 33
- 239000007788 liquid Substances 0.000 claims abstract description 22
- 210000004072 lung Anatomy 0.000 claims abstract description 22
- 210000003437 trachea Anatomy 0.000 claims abstract description 10
- 238000000889 atomisation Methods 0.000 claims abstract description 8
- 210000000867 larynx Anatomy 0.000 claims abstract description 7
- 239000003595 mist Substances 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 5
- 210000000214 mouth Anatomy 0.000 abstract description 9
- 210000001331 nose Anatomy 0.000 abstract description 8
- 210000002345 respiratory system Anatomy 0.000 abstract description 7
- 208000035473 Communicable disease Diseases 0.000 abstract description 5
- 208000015181 infectious disease Diseases 0.000 abstract description 4
- 206010022000 influenza Diseases 0.000 abstract description 4
- 210000000056 organ Anatomy 0.000 abstract description 4
- 241000711573 Coronaviridae Species 0.000 abstract description 3
- 206010035737 Pneumonia viral Diseases 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 208000009421 viral pneumonia Diseases 0.000 abstract description 3
- 208000025370 Middle East respiratory syndrome Diseases 0.000 abstract description 2
- 230000007123 defense Effects 0.000 abstract description 2
- 239000002324 mouth wash Substances 0.000 abstract description 2
- 229940051866 mouthwash Drugs 0.000 abstract description 2
- 210000003300 oropharynx Anatomy 0.000 abstract description 2
- 230000035945 sensitivity Effects 0.000 abstract description 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000003800 pharynx Anatomy 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
- 229920000153 Povidone-iodine Polymers 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 229960001621 povidone-iodine Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000003886 intestinal anastomosis Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000010352 nasal breathing Effects 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
- A61K31/79—Polymers of vinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
Abstract
本发明是涉及一种用含碘消毒液雾化防治病毒性呼吸道疾病的方法，可广泛应用于病毒性肺炎和病毒性流感、感冒的防治，尤其对防治呼吸系统病毒感染具有特殊意义。2019年一篇德国科学家发表在《传染病学》上的论文是指出，可以用碘伏对抗传染病，碘伏漱口液能显著减少口腔和口咽部的病毒载量，可以有效对抗SARS和MERS这两种冠状病毒的传染。本发明是基于人体肺部及呼吸道构造的特殊性，把人体肺部和呼吸道看作是相对对外部开放的特殊器官，且大部分病毒对碘的敏感性思路设计。先将液体含碘液体(优选碘伏)雾化，然后通过口鼻吸入，依次通过喉部、气管，再进入人体肺中，达到抑制或杀灭肺泡以及呼吸道中病毒的目的。本发明还适用于对健康人群日常的病毒防御。
Description
技术领域
本发明属于医疗领域，特别是涉及一种用含碘消毒液雾化防治病毒性呼吸道疾病的方法，可广泛应用于病毒性肺炎以及流感、感冒等的防治，尤其对防治呼吸系统冠状病毒感染具有特殊意义。
背景技术
众所周知，导致肺炎的微生物主要有两类，一类是细菌，一类是病毒。治疗细菌性肺炎主要用抗生素，这方面已经有了比较成熟的技术。但是对于病毒性肺炎，由于病毒自身结构的特殊性，目前全世界仍然束手无策。
2019年一篇德国科学家发表在《传染病学》上的论文指出，可以用碘伏对抗传染病，碘伏漱口液能显著减少口腔和口咽部的病毒载量，可以有效对抗SARS和MERS这两种冠状病毒的传染。Infectious Disease Management and Control with Povidone Iodine.
所以，用碘伏液或碘酒液可以有效杀灭病毒，可以适当替代酒精使用，碘伏相对于酒精的另一大优点是不会燃烧爆炸。碘伏强大的抗病毒能力，早在1997年就由日本盛冈悦爱总医院的医生们研究过，相关成果发表在皮肤病学期刊上《聚维酮碘对人体病毒的灭活作用及其与其他消毒剂的比较》，研究结果说：碘伏可以有效灭杀包膜病毒(冠状病毒就是包膜病毒)和非包膜病毒，实验测试了流感、腺病毒、麻疹、HIV、脊髓灰质炎(类型1和3)、柯萨奇病毒、单纯疱疹、风疹等常见病毒。科学家发现碘是控制感染的有效方法。David Derry博士在回顾碘的发展历程时写道：“1945年，Burnet和Stone发现，在老鼠的鼻子上涂抹碘酒，可防止老鼠被雾中的活流感病毒感染。他们建议，戴上用碘浸泡过的口罩可以阻止病毒传播。他们还建议医护人员在施用碘气雾剂的房间内检查和治疗高度感染患者。”
他引用的研究在1945年9月发表于《澳大利亚实验生物学与医学科学杂志》(Australian Journal of Experimental Biology and Medical Science)。
众所周知，病毒是由蛋白质外壳包裹的可复制遗传物质的微生物，当其进入人体之后，一般的口服或注射药物都很难杀灭，或者说，能够杀灭病毒的药物，也必然会对人体有很强的刺激甚至毒害作用，常常会对人体细胞也造成严重损害，所以病毒只能在人体体外的情况进行消毒杀灭。但是，考虑到人体肺部构造的特殊性，我们可以把人体肺部看作是相对对外部开放的特殊器官，也就是说，人体肺部器官是随时与外部气体交互开放的器官。同时，基于大部分病毒对碘伏或碘酒的敏感性，当雾化的碘伏或碘酒吸入人体肺部时，碘伏或碘酒就能直接接触到病毒，或者虽然病毒已经侵入到肺部的细胞中，碘伏或碘酒也可以率先浸润肺部细胞从而以较高浓度接触到病毒体内从而杀灭病毒。
发明内容
将液体碘伏或碘酒置入雾化器中，开启雾化器，使碘伏或碘酒液体雾化成为雾状碘伏或碘酒，然后通过口鼻吸入人体肺中，使碘伏或碘酒直接与肺泡里的病毒接触，从而达到抑制或杀灭从口腔咽部到肺叶肺泡中病毒的目的。
实现本发明所采取的具体技术方案是，将适当浓度的液体碘伏或碘酒置入雾化器中，开启雾化器，使碘伏或碘酒液体雾化成为雾状碘伏或碘酒，然后通过口鼻吸入，依次通过喉部、气管，再进入人体肺中，达到抑制或杀灭肺泡以及呼吸道中病毒的目的。所述雾化器包括超声波雾化器，加热雾化器和喷雾器。本发明还适用于对健康人群日常的病毒防御，也就是说，健康人群中，在没有确定是否感染病毒的情况下，每天吸入一定量的雾化碘伏或碘酒，对肺部进行消毒处理，有毒消毒，无毒祛疑。而雾化消毒所摄入的碘伏或碘酒量非常微小，且对身体无明显刺激不适。事实上，碘元素是人体必需元素，许多地方人群常常碘缺乏，需要格外补碘，可见，吸入一定量的碘，对身体影响不大。需要注意的是，使用本发明，要避免与碘伏或碘酒配伍禁忌的药物使用，特别是当使用碘酒时，要防止产生双硫仑反应。
使用本技术方案的有益效果是，用刺激性和毒副作用尽可能低的药物，对肺部器官进行类似体外杀毒且近似靶向治疗设计来杀灭病毒。碘伏或碘酒对人体刺激非常微小，进入人体之后被血液稀释，因此可以看作是毒性最低而疗效最显著的方法。本设计经过实测，碘伏或碘酒经雾化后通过口鼻吸入肺中，无明显刺激和不适感觉。本发明优选碘伏溶液雾化方案，因为碘伏相对于碘酒来说，刺激性更小，常规医疗上用于粘膜消毒，甚至于还用于肠道手术的肠吻合消毒，因此其安全性更是公认的。
具体实施方式
将碘伏或碘酒液体置入超声波雾化器中，开启超声波雾化器，使碘伏或碘酒液体雾化成为雾状碘伏或碘酒，然后通过口鼻吸入，依次通过喉部、气管，再进入人体肺中，达到抑制或杀灭喉部、气管表面和肺泡表面以及肺泡细胞中病毒的目的。
实施方式1
将碘浓度370mg/ml的碘伏液体置入超声波雾化器(加湿器)中，开启超声波雾化器，使碘伏液体雾化成为雾状碘伏，针对呼吸系统病毒感染者，使患者通过鼻腔呼吸吸入人体肺中，达到抑制或杀灭肺泡中病毒的目的。
实施方式2
将碘酒液体置入加热容器中，开启加热雾化器，使碘酒液体雾化成为碘酒蒸汽，然后通过口鼻吸入，依次通过喉部、气管，再进入人体肺中，达到抑制或杀灭肺泡以及呼吸道中病毒的目的。
实施方式3
将用医用碘伏液体置入喷雾器中，开启喷雾器，使碘伏液体雾化成为雾状碘伏，然后通过口鼻吸入，依次通过喉部、气管，再进入人体肺中，达到抑制或杀灭呼吸道中病毒，从而起到防治感冒和流感的目的。
需要说明的是，超声波雾化器、加热雾化器、喷雾器等，都是现有技术和产品，无须赘述，优选超声波雾化器，也即超声波加湿器。
Claims (4)
1.一种用含碘消毒液雾化防治病毒性呼吸道疾病的方法，其特征是，将碘伏或碘酒液体置入雾化器中，开启雾化器，使碘伏或碘酒液体雾化成为雾状，然后通过口鼻吸入，依次通过喉部、气管，再进入人体肺中，雾状碘伏或碘酒沉积其表面，达到抑制或杀灭其表面乃至肺泡细胞内病毒的目的。
2.根据权利要求1所述用含碘消毒液雾化防治病毒性呼吸道疾病的方法，其特征是，将碘伏或碘酒液体置入超声波雾化器中，开启超声波雾化器，使碘伏或碘酒液体雾化成为雾状，然后通过口鼻吸入，依次通过喉部、气管，再进入人体肺中，达到抑制或杀灭其表面乃至肺泡细胞内病毒的目的。
3.根据权利要求1所述用含碘消毒液雾化防治病毒性呼吸道疾病的方法，其特征是，将碘伏或碘酒液体置入加热雾化器中，开启加热雾化器，使碘伏或碘酒液体雾化成为雾状，然后通过口鼻吸入，依次通过喉部、气管，再进入人体肺中，达到抑制或杀灭其表面乃至肺泡细胞内病毒的目的。
4.根据权利要求1所述用含碘消毒液雾化防治病毒性呼吸道疾病的方法，其特征是，将碘伏或碘酒液体置入喷雾器中，开启喷雾器，使碘伏或碘酒液体雾化成为雾状，然后通过口鼻吸入，依次通过喉部、气管，再进入人体肺中，达到抑制或杀灭其表面乃至肺泡细胞内病毒的目的。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010217112 | 2020-03-17 | ||
| CN2020102171128 | 2020-03-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111956660A true CN111956660A (zh) | 2020-11-20 |
Family
ID=73365061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010781011.3A Pending CN111956660A (zh) | 2020-03-17 | 2020-07-29 | 用含碘消毒液雾化防治病毒性呼吸道疾病的方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111956660A (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111904976A (zh) * | 2020-04-17 | 2020-11-10 | 姚志勇 | 含碘制剂体内杀灭微生物的方法 |
| CN112791097A (zh) * | 2020-11-27 | 2021-05-14 | 金玉东 | 碘在制备预防、治疗呼吸道感染性疾病的药物中的应用以及制备低粒径含碘气溶胶的方法 |
| CN112807385A (zh) * | 2021-01-13 | 2021-05-18 | 陈文兵 | 治疗肺炎的配方及治疗肺炎的颗粒冲剂的智能生产设备 |
| CN113504339A (zh) * | 2021-06-02 | 2021-10-15 | 湖南中净生物科技有限公司 | 一种三级病毒烟雾灭活效果测试方法 |
-
2020
- 2020-07-29 CN CN202010781011.3A patent/CN111956660A/zh active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111904976A (zh) * | 2020-04-17 | 2020-11-10 | 姚志勇 | 含碘制剂体内杀灭微生物的方法 |
| CN112791097A (zh) * | 2020-11-27 | 2021-05-14 | 金玉东 | 碘在制备预防、治疗呼吸道感染性疾病的药物中的应用以及制备低粒径含碘气溶胶的方法 |
| WO2022111497A1 (zh) * | 2020-11-27 | 2022-06-02 | 金玉东 | 碘在制备预防、治疗呼吸道感染性疾病的药物中的应用 |
| CN112807385A (zh) * | 2021-01-13 | 2021-05-18 | 陈文兵 | 治疗肺炎的配方及治疗肺炎的颗粒冲剂的智能生产设备 |
| CN113504339A (zh) * | 2021-06-02 | 2021-10-15 | 湖南中净生物科技有限公司 | 一种三级病毒烟雾灭活效果测试方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111956660A (zh) | 用含碘消毒液雾化防治病毒性呼吸道疾病的方法 | |
| WO2022111497A1 (zh) | 碘在制备预防、治疗呼吸道感染性疾病的药物中的应用 | |
| US20200268656A1 (en) | Nebulized Ethanol for Internal Disinfecting and Improvement | |
| CN111973577A (zh) | 用雾化酒精防治病毒性肺炎和病毒性流感、感冒的方法 | |
| RU2353376C1 (ru) | Способ лечения и профилактики бронхопневмонии у телят и поросят | |
| US20220054539A1 (en) | Disinfection and deodorizing of pap equipment using low concentration hypochlorous acid solutions | |
| US20230013142A1 (en) | Iodine compounds for treating respiratory pathogens | |
| US20220323489A1 (en) | Hypochlorous acid solutions for the treatment of drug resistant pneumonia and tuberculosis | |
| CN103933309A (zh) | 用吸入雾化的紫蒜液方法治疗肺结核 | |
| US20210177892A1 (en) | Prevention and treatment of infectious disease using low concentration hypochlorous acid solutions | |
| WO2022047188A1 (en) | Process of using chlorine dioxide for the attenuation and or treatment of coronavirus diseases | |
| WO2022032468A1 (zh) | 抗呼吸道病毒的装置、方法及药物 | |
| CN116568138A (zh) | 用于消毒、治疗和预防微生物感染的组合物和方法 | |
| Frippiat et al. | In vitro virucidal activity of nebulized citrate-complexed silver nanoparticles against equine herpesvirus-1 and murine norovirus | |
| CN201862088U (zh) | 医用灭菌性雾化器 | |
| TWI807655B (zh) | 用於預防及治療細菌及病毒感染之呼吸道病症的水溶液醫藥組合物及其行動防護給藥裝置 | |
| CN111265794A (zh) | 雾化中药气体尘埃过滤病毒隔离灭活呼吸器 | |
| US11179415B1 (en) | Process of using chlorine dioxide for the attenuation and/or treatment of Coronavirus diseases such as COVID-19 and disabling, treating or attenuating the SARS CoV-2 virus, and its future infective variants | |
| Zachar | Respiratory Infections Early-Stage Medication: Inhalation Formulation & Dosage of PVP Iodine | |
| US20210401876A1 (en) | Pharmaceutical composition of chlorine for treatment of respiratory viral infection | |
| CN1194673C (zh) | 抗病毒雾化吸入药液 | |
| Zachar | Inhalation Formulation & Dosage of PVP Iodine for Respiratory Infections Treatment | |
| KR20250016360A (ko) | 고농도 분자 요오드를 함유하는 급성 호흡기 감염성 질환 예방 및 치료 조성물 및 방법 | |
| CN119015546A (zh) | 酒精熏疗器 | |
| DK202170549A1 (en) | Medicament for inhalation or breathing, and inhaler or breathing device comprising same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20201120 |